Does the media favor JNJ or NVO?

In the previous week, Novo Nordisk A/S had 28 more articles in the media than Johnson & Johnson. MarketBeat recorded 78 mentions for Novo Nordisk A/S and 50 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 0.81 beat Novo Nordisk A/S's score of 0.43 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 30 Very Positive mention(s) 6 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Novo Nordisk A/S 36 Very Positive mention(s) 14 Positive mention(s) 15 Neutral mention(s) 12 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings and valuation, NVO or MRK?

Merck & Co., Inc. has higher revenue and earnings than Novo Nordisk A/S. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $46.80B 3.70 $15.51B $4.09 9.49 Merck & Co., Inc. $65.01B 5.65 $18.25B $1.25 119.00

Does the media refer more to NVO or MRK?

In the previous week, Novo Nordisk A/S had 45 more articles in the media than Merck & Co., Inc.. MarketBeat recorded 78 mentions for Novo Nordisk A/S and 33 mentions for Merck & Co., Inc.. Merck & Co., Inc.'s average media sentiment score of 0.70 beat Novo Nordisk A/S's score of 0.43 indicating that Merck & Co., Inc. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 36 Very Positive mention(s) 14 Positive mention(s) 15 Neutral mention(s) 12 Negative mention(s) 1 Very Negative mention(s) Neutral Merck & Co., Inc. 19 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive

Is NVS or NVO more profitable?

Novo Nordisk A/S has a net margin of 35.36% compared to Novartis' net margin of 23.29%. Novo Nordisk A/S's return on equity of 58.61% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets Novartis 23.29% 38.56% 14.47% Novo Nordisk A/S 35.36% 58.61% 20.91%

Does the media favor NVS or NVO?

In the previous week, Novo Nordisk A/S had 61 more articles in the media than Novartis. MarketBeat recorded 78 mentions for Novo Nordisk A/S and 17 mentions for Novartis. Novartis' average media sentiment score of 0.77 beat Novo Nordisk A/S's score of 0.43 indicating that Novartis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Novo Nordisk A/S 36 Very Positive mention(s) 14 Positive mention(s) 15 Neutral mention(s) 12 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer NVO or AZN?

In the previous week, Novo Nordisk A/S had 61 more articles in the media than Astrazeneca. MarketBeat recorded 78 mentions for Novo Nordisk A/S and 17 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 0.92 beat Novo Nordisk A/S's score of 0.43 indicating that Astrazeneca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 36 Very Positive mention(s) 14 Positive mention(s) 15 Neutral mention(s) 12 Negative mention(s) 1 Very Negative mention(s) Neutral Astrazeneca 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is NVO or PFE more profitable?

Novo Nordisk A/S has a net margin of 35.36% compared to Pfizer's net margin of 6.80%. Novo Nordisk A/S's return on equity of 58.61% beat Pfizer's return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 35.36% 58.61% 20.91% Pfizer 6.80% 19.63% 8.46%

Does the media prefer NVO or PFE?

In the previous week, Novo Nordisk A/S had 28 more articles in the media than Pfizer. MarketBeat recorded 78 mentions for Novo Nordisk A/S and 50 mentions for Pfizer. Novo Nordisk A/S's average media sentiment score of 0.43 beat Pfizer's score of 0.41 indicating that Novo Nordisk A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 36 Very Positive mention(s) 14 Positive mention(s) 15 Neutral mention(s) 12 Negative mention(s) 1 Very Negative mention(s) Neutral Pfizer 17 Very Positive mention(s) 6 Positive mention(s) 20 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Neutral

Novo Nordisk A/S (NVO) Competitors

$38.81 +0.01 (+0.03%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$38.80 -0.02 (-0.04%)

As of 09/25/2026 08:00 PM Eastern

Compare

NVO vs. JNJ, MRK, NVS, AZN, and PFE

Should you buy Novo Nordisk A/S stock or one of its competitors? Novo Nordisk A/S's main competitors and comparable companies include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Novartis (NVS), Astrazeneca (AZN), and Pfizer (PFE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Novo Nordisk A/S compare to Johnson & Johnson?

Johnson & Johnson (NYSE:JNJ) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

In the previous week, Novo Nordisk A/S had 28 more articles in the media than Johnson & Johnson. MarketBeat recorded 78 mentions for Novo Nordisk A/S and 50 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 0.81 beat Novo Nordisk A/S's score of 0.43 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	30 Very Positive mention(s)	6 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Novo Nordisk A/S	36 Very Positive mention(s)	14 Positive mention(s)	15 Neutral mention(s)	12 Negative mention(s)	1 Very Negative mention(s)	Neutral

69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Novo Nordisk A/S has a net margin of 35.36% compared to Johnson & Johnson's net margin of 21.48%. Novo Nordisk A/S's return on equity of 58.61% beat Johnson & Johnson's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.48%	32.42%	13.35%
Novo Nordisk A/S	35.36%	58.61%	20.91%

Johnson & Johnson presently has a consensus price target of $274.13, indicating a potential upside of 0.94%. Novo Nordisk A/S has a consensus price target of $64.94, indicating a potential upside of 67.31%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.80
Novo Nordisk A/S	1 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11

Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 2.0%. Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 2.1%. Johnson & Johnson pays out 62.1% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 20.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has increased its dividend for 64 consecutive years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Johnson & Johnson has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Johnson & Johnson has higher revenue and earnings than Novo Nordisk A/S. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$97.93B	6.68	$26.80B	$8.63	31.47
Novo Nordisk A/S	$46.80B	3.70	$15.51B	$4.09	9.49

Summary

Johnson & Johnson beats Novo Nordisk A/S on 12 of the 20 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Merck & Co., Inc.?

Novo Nordisk A/S (NYSE:NVO) and Merck & Co., Inc. (NYSE:MRK) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Novo Nordisk A/S currently has a consensus price target of $64.94, suggesting a potential upside of 67.31%. Merck & Co., Inc. has a consensus price target of $154.24, suggesting a potential upside of 3.69%. Given Novo Nordisk A/S's higher probable upside, equities research analysts clearly believe Novo Nordisk A/S is more favorable than Merck & Co., Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11
Merck & Co., Inc.	0 Sell rating(s)	7 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.71

Merck & Co., Inc. has higher revenue and earnings than Novo Nordisk A/S. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	3.70	$15.51B	$4.09	9.49
Merck & Co., Inc.	$65.01B	5.65	$18.25B	$1.25	119.00

In the previous week, Novo Nordisk A/S had 45 more articles in the media than Merck & Co., Inc.. MarketBeat recorded 78 mentions for Novo Nordisk A/S and 33 mentions for Merck & Co., Inc.. Merck & Co., Inc.'s average media sentiment score of 0.70 beat Novo Nordisk A/S's score of 0.43 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	36 Very Positive mention(s)	14 Positive mention(s)	15 Neutral mention(s)	12 Negative mention(s)	1 Very Negative mention(s)	Neutral
Merck & Co., Inc.	19 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive

Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 2.1%. Merck & Co., Inc. pays an annual dividend of $3.40 per share and has a dividend yield of 2.3%. Novo Nordisk A/S pays out 20.0% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 272.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. has raised its dividend for 14 consecutive years. Merck & Co., Inc. is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Novo Nordisk A/S has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Merck & Co., Inc. has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Novo Nordisk A/S has a net margin of 35.36% compared to Merck & Co., Inc.'s net margin of 4.77%. Novo Nordisk A/S's return on equity of 58.61% beat Merck & Co., Inc.'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	35.36%	58.61%	20.91%
Merck & Co., Inc.	4.77%	16.73%	6.13%

Summary

Merck & Co., Inc. beats Novo Nordisk A/S on 11 of the 19 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Novartis?

Novartis (NYSE:NVS) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Novo Nordisk A/S has a net margin of 35.36% compared to Novartis' net margin of 23.29%. Novo Nordisk A/S's return on equity of 58.61% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	23.29%	38.56%	14.47%
Novo Nordisk A/S	35.36%	58.61%	20.91%

13.1% of Novartis shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 0.0% of Novartis shares are owned by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Novartis has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 2.1%. Novartis pays out 46.5% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 20.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, Novo Nordisk A/S had 61 more articles in the media than Novartis. MarketBeat recorded 78 mentions for Novo Nordisk A/S and 17 mentions for Novartis. Novartis' average media sentiment score of 0.77 beat Novo Nordisk A/S's score of 0.43 indicating that Novartis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Novo Nordisk A/S	36 Very Positive mention(s)	14 Positive mention(s)	15 Neutral mention(s)	12 Negative mention(s)	1 Very Negative mention(s)	Neutral

Novartis presently has a consensus price target of $153.00, indicating a potential upside of 5.16%. Novo Nordisk A/S has a consensus price target of $64.94, indicating a potential upside of 67.31%. Given Novo Nordisk A/S's higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	0 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
Novo Nordisk A/S	1 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11

Novo Nordisk A/S has lower revenue, but higher earnings than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.09	$13.98B	$6.63	21.94
Novo Nordisk A/S	$46.80B	3.70	$15.51B	$4.09	9.49

Summary

Novartis and Novo Nordisk A/S tied by winning 9 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Astrazeneca?

Novo Nordisk A/S (NYSE:NVO) and Astrazeneca (NYSE:AZN) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

In the previous week, Novo Nordisk A/S had 61 more articles in the media than Astrazeneca. MarketBeat recorded 78 mentions for Novo Nordisk A/S and 17 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 0.92 beat Novo Nordisk A/S's score of 0.43 indicating that Astrazeneca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	36 Very Positive mention(s)	14 Positive mention(s)	15 Neutral mention(s)	12 Negative mention(s)	1 Very Negative mention(s)	Neutral
Astrazeneca	11 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 2.1%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.6%. Novo Nordisk A/S pays out 20.0% of its earnings in the form of a dividend. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novo Nordisk A/S has higher earnings, but lower revenue than Astrazeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	3.70	$15.51B	$4.09	9.49
Astrazeneca	$58.74B	4.40	$10.23B	$6.69	24.92

Novo Nordisk A/S has a net margin of 35.36% compared to Astrazeneca's net margin of 17.02%. Novo Nordisk A/S's return on equity of 58.61% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	35.36%	58.61%	20.91%
Astrazeneca	17.02%	31.45%	13.20%

Novo Nordisk A/S has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Novo Nordisk A/S presently has a consensus target price of $64.94, suggesting a potential upside of 67.31%. Astrazeneca has a consensus target price of $206.67, suggesting a potential upside of 23.98%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11
Astrazeneca	1 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.72

Summary

Novo Nordisk A/S and Astrazeneca tied by winning 9 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Pfizer?

Novo Nordisk A/S (NYSE:NVO) and Pfizer (NYSE:PFE) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 0.6% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Novo Nordisk A/S has a net margin of 35.36% compared to Pfizer's net margin of 6.80%. Novo Nordisk A/S's return on equity of 58.61% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	35.36%	58.61%	20.91%
Pfizer	6.80%	19.63%	8.46%

Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 2.1%. Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.0%. Novo Nordisk A/S pays out 20.0% of its earnings in the form of a dividend. Pfizer pays out 226.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Novo Nordisk A/S presently has a consensus target price of $64.94, suggesting a potential upside of 67.31%. Pfizer has a consensus target price of $28.39, suggesting a potential downside of 1.00%. Given Novo Nordisk A/S's higher possible upside, equities analysts clearly believe Novo Nordisk A/S is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19

Novo Nordisk A/S has higher earnings, but lower revenue than Pfizer. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	3.70	$15.51B	$4.09	9.49
Pfizer	$62.58B	2.61	$7.77B	$0.76	37.73

In the previous week, Novo Nordisk A/S had 28 more articles in the media than Pfizer. MarketBeat recorded 78 mentions for Novo Nordisk A/S and 50 mentions for Pfizer. Novo Nordisk A/S's average media sentiment score of 0.43 beat Pfizer's score of 0.41 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	36 Very Positive mention(s)	14 Positive mention(s)	15 Neutral mention(s)	12 Negative mention(s)	1 Very Negative mention(s)	Neutral
Pfizer	17 Very Positive mention(s)	6 Positive mention(s)	20 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral

Novo Nordisk A/S has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

Summary

Novo Nordisk A/S beats Pfizer on 11 of the 20 factors compared between the two stocks.

Get Novo Nordisk A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVO vs. The Competition

Export

Metric	Novo Nordisk A/S	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$173.30B	$12.68B	$7.35B	$23.01B
Dividend Yield	2.10%	2.62%	2.52%	3.68%
P/E Ratio	9.49	797.38	275.82	27.98
Price / Sales	3.70	754.49	616.73	21.73
Price / Cash	8.28	15.22	28.02	19.25
Price / Book	5.90	10.50	10.48	4.69
Net Income	$15.51B	$2.85B	$3.51B	$1.07B
7 Day Performance	-2.46%	-1.14%	-1.34%	-1.42%
1 Month Performance	-14.87%	-1.60%	-3.50%	-4.73%
1 Year Performance	-30.20%	1.31%	15.02%	7.73%

Novo Nordisk A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVO Novo Nordisk A/S	4.4463 of 5 stars	$38.81 +0.0%	$64.94 +67.3%	-30.2%	$173.30B	$46.80B	9.49	69,505	Trending News
JNJ Johnson & Johnson	4.4367 of 5 stars	$269.80 +0.2%	$274.13 +1.6%	+51.1%	$649.71B	$94.19B	31.24	138,200	Trending News Analyst Forecast
MRK Merck & Co., Inc.	3.7674 of 5 stars	$147.99 -1.9%	$154.24 +4.2%	+89.5%	$365.24B	$65.01B	118.43	75,000	Trending News
NVS Novartis	4.2308 of 5 stars	$142.49 +0.9%	$153.00 +7.4%	+17.6%	$271.51B	$54.53B	21.46	75,267	Analyst Revision
AZN Astrazeneca	4.9415 of 5 stars	$165.70 -1.6%	$206.67 +24.7%	N/A	$256.29B	$58.74B	24.70	96,100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NVO) was last updated on 9/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Competitors

NVO vs. JNJ, MRK, NVS, AZN, and PFE

How does Novo Nordisk A/S compare to Johnson & Johnson?

Summary

How does Novo Nordisk A/S compare to Merck & Co., Inc.?

Summary

How does Novo Nordisk A/S compare to Novartis?

Summary

How does Novo Nordisk A/S compare to Astrazeneca?

Summary

How does Novo Nordisk A/S compare to Pfizer?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novo Nordisk A/S (NVO) Competitors

NVO vs. JNJ, MRK, NVS, AZN, and PFE

How does Novo Nordisk A/S compare to Johnson & Johnson?

Does the media favor JNJ or NVO?

Do institutionals & insiders hold more shares of JNJ or NVO?

Is JNJ or NVO more profitable?

Do analysts prefer JNJ or NVO?

Is JNJ or NVO a better dividend stock?

Which has more risk and volatility, JNJ or NVO?

Which has preferable earnings & valuation, JNJ or NVO?

Summary

How does Novo Nordisk A/S compare to Merck & Co., Inc.?

Do analysts recommend NVO or MRK?

Which has higher earnings and valuation, NVO or MRK?

Does the media refer more to NVO or MRK?

Is NVO or MRK a better dividend stock?

Which has more risk and volatility, NVO or MRK?

Do institutionals & insiders believe in NVO or MRK?

Is NVO or MRK more profitable?

Summary

How does Novo Nordisk A/S compare to Novartis?

Is NVS or NVO more profitable?

Do institutionals and insiders believe in NVS or NVO?

Which has more risk and volatility, NVS or NVO?

Is NVS or NVO a better dividend stock?

Does the media favor NVS or NVO?

Do analysts prefer NVS or NVO?

Which has better earnings and valuation, NVS or NVO?

Summary

How does Novo Nordisk A/S compare to Astrazeneca?

Does the media prefer NVO or AZN?

Is NVO or AZN a better dividend stock?

Which has better valuation & earnings, NVO or AZN?

Is NVO or AZN more profitable?

Which has more risk and volatility, NVO or AZN?

Do institutionals & insiders hold more shares of NVO or AZN?

Do analysts prefer NVO or AZN?

Summary

How does Novo Nordisk A/S compare to Pfizer?

Do insiders and institutionals hold more shares of NVO or PFE?

Is NVO or PFE more profitable?

Is NVO or PFE a better dividend stock?

Do analysts recommend NVO or PFE?

Which has better earnings & valuation, NVO or PFE?

Does the media prefer NVO or PFE?

Which has more risk and volatility, NVO or PFE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools